Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies using its proprietary TORPEDO platform, which leverages the ubiquitin-proteasome system to degrade disease-causing proteins. The company's lead programs target oncology indications, with pipeline candidates in Phase 1/2 trials addressing difficult-to-drug targets in hematologic malignancies and solid tumors. As a pre-revenue biotech with $200M market cap and 7.8x current ratio, the stock trades on clinical trial readouts, partnership announcements, and cash runway visibility.
C4 operates a platform-based model where it develops proprietary degrader molecules targeting previously undruggable proteins, then either advances candidates internally through clinical trials or out-licenses programs to larger pharmaceutical partners for upfront payments, research funding, milestone payments (potentially $500M+ per program), and royalties on commercial sales. The TORPEDO platform's competitive advantage lies in its ability to selectively degrade target proteins rather than inhibit them, potentially offering superior efficacy and safety profiles. Current 77.8% gross margin reflects minimal COGS on collaboration revenue, while -290.7% operating margin is typical for clinical-stage biotechs burning cash on R&D and clinical trials.
Clinical trial data readouts for lead degrader programs (Phase 1/2 safety, efficacy, pharmacokinetic data)
Partnership announcements with big pharma for platform validation and non-dilutive funding
Regulatory milestones (IND filings, FDA feedback, orphan drug designations)
Cash position updates and equity financing announcements affecting dilution and runway
Competitive developments in targeted protein degradation space (molecular glue degraders, PROTACs from Arvinas, Nurix)
Preclinical data demonstrating platform expansion into new therapeutic areas or target classes
Clinical trial failure risk: Phase 1/2 programs face high attrition rates with potential for safety issues, lack of efficacy, or unfavorable pharmacokinetics that could terminate programs and destroy shareholder value
Regulatory pathway uncertainty: Novel protein degradation mechanism may face FDA scrutiny requiring additional studies or biomarker development, extending timelines and increasing capital requirements
Platform validation risk: TORPEDO technology unproven at commercial scale; failure of lead programs could invalidate entire platform thesis and partnership interest
Competitive technology displacement: Molecular glue degraders and next-generation PROTACs from better-capitalized competitors could render C4's approach obsolete
Well-funded competitors (Arvinas $1B+ market cap, Kymera, Nurix) advancing similar targeted protein degradation platforms with potentially superior clinical data or broader pipelines
Big pharma internal degrader programs (Roche, Bristol Myers Squibb) leveraging greater resources and existing oncology franchises to capture market share
Patent landscape complexity in protein degradation space creating freedom-to-operate risks and potential litigation
Cash runway risk: With -$100M annual operating cash flow and $200M market cap, company likely needs equity financing within 18-24 months, creating dilution risk for existing shareholders
Equity financing risk: Volatile biotech markets may force capital raises at unfavorable valuations, particularly if clinical data disappoints or broader risk-off sentiment prevails
Partnership dependency: Limited revenue diversification means loss of key collaboration partner could materially impact cash position and strategic options
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is driven by scientific milestones rather than economic cycles. However, capital markets access for equity financing and M&A valuations are cyclically sensitive, affecting ability to raise cash and exit opportunities.
Rising rates negatively impact valuation multiples for pre-revenue biotechs as future cash flows are discounted more heavily, compressing price/sales multiples. Higher rates also increase opportunity cost of capital for venture and growth investors, reducing appetite for high-risk clinical assets. Additionally, cash held in money market instruments benefits from higher yields, partially offsetting burn rate. The 6.3x price/sales multiple is vulnerable to rate-driven multiple compression.
Minimal direct credit exposure as the company has low debt (0.23x debt/equity) and does not rely on credit markets for operations. However, tighter credit conditions can reduce big pharma M&A activity and partnership appetite, limiting exit opportunities and collaboration potential.
growth - Attracts high-risk, high-reward biotech specialists and venture-style investors betting on binary clinical outcomes and platform validation. The 28.8% one-year return and recent positive momentum (13.9% three-month return) appeal to momentum traders around catalyst events. Not suitable for value or income investors given pre-revenue status, negative cash flows, and lack of dividends. Institutional ownership likely concentrated among dedicated healthcare funds and crossover investors.
high - Clinical-stage biotechs exhibit extreme volatility around binary events (trial readouts, FDA decisions, partnership announcements). Small market cap ($200M) and low float amplify price swings. Stock likely trades with beta >1.5 to broader biotech indices, with potential for 20-50% single-day moves on material news. Recent 16.4% EPS growth is misleading given negative earnings base.